Molar, Third, Photobiomodulation, Photobiomodulation Therapy, Third Molar Surgery
Conditions
Keywords
photobiomodulation, LED, 830 nm, third molar surgery
Brief summary
LED Therapy for third molar surgery
Detailed description
LED Therapy using 830 nm in the mandibular third molar surgery
Interventions
DEVICEphotobiomodulation
830 nm LED was used to irradiate the post-extraction area
DRUGAntibiotic
ibuprofen 0.3 g bid for 3 days, metronidazole 0.1 g tid, and cefaclor 0.375 g bid for 7 days after surgery
Sponsors
Huashan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
This study was a double-blind study in which the patient, the surgeon, and the statistician were all unaware of whether the patient received treatment or a placebo control light . Only the operator using the LED light was aware of this information. The assigned group was recorded on sealed and opaque envelopes. These cards were prepared by an independent person who was not involved in the study protocol. Once the patient underwent extraction and agreed to participate in this trial, this independent person opened the envelope to reveal the allocation.
Intervention model description
Patients who underwent mandibular third molar extraction
Eligibility
Sex/Gender
ALL
Age
20 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
1. Healthy Asians; 2. 20-55 years old; 3. Having mandibular third molars that are inappropriately erupted and need to be extracted due to caries, orthodontic reasons and/or periodontal disease;
Exclusion criteria
1. Underlying diseases: diabetes, cardiovascular disease, coagulation disorder, osteoporosis, hypertension, neurological disease, psychological disorder, tumor, systemic infection or cyst at the extraction site; 2. Women who are preparing for pregnancy, pregnant or breastfeeding; 3. Medication history: use of analgesics, anti-inflammatory drugs and/or antibacterial drugs 2 weeks before tooth extraction, need for systemic medication other than acetaminophen after surgery, allergy to acetaminophen, use of anticoagulants, bisphosphonates; 4. Bad habits, such as addicted to smoking, drinking, etc.; 5. Volunteers who have recently participated in other clinical trials;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain | Day 7 | Visual Analogue Scale，VAS |
| Swelling | Day 3; Day 7 | Facial swelling was measured in 2 planes: the distance between the tragus and lip commissure and the distance between the gonion and external canthus of the eye. |
| Trismus | Day 3; Day 7 | Trismus was evaluated by measuring the maximum mouth opening between the edges of the upper and lower central incisors with a calibrated ruler. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life score | Day 3; Day 7 | OHIP-14 Scale |
Countries
China
Contacts
Primary ContactYanjun Jane Dan, Medical Doctor
Outcome results
None listed